Critical Comparison: Bio-Path (BPTH) versus Its Peers

Profitability

This table compares Bio-Path and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Bio-Path	N/A	-2,842.40%	-337.48%
Bio-Path Competitors	-4,539.09%	-243.53%	-48.20%

Institutional & Insider Ownership

5.7% of Bio-Path shares are owned by institutional investors. Comparatively, 33.6% of shares of all “Pharmaceutical preparations” companies are owned by institutional investors. 0.7% of Bio-Path shares are owned by insiders. Comparatively, 14.2% of shares of all “Pharmaceutical preparations” companies are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Earnings & Valuation

This table compares Bio-Path and its rivals revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Bio-Path	N/A	-$16.08 million	-0.06
Bio-Path Competitors	$326.27 million	-$30.68 million	-5.84

Bio-Path’s rivals have higher revenue, but lower earnings than Bio-Path. Bio-Path is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.

Volatility and Risk

Bio-Path has a beta of -0.24, suggesting that its stock price is 124% less volatile than the S&P 500. Comparatively, Bio-Path’s rivals have a beta of 10.15, suggesting that their average stock price is 915% more volatile than the S&P 500.

Summary

Bio-Path rivals beat Bio-Path on 6 of the 9 factors compared.

Bio-Path Company Profile

Bio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused RNAi nanoparticle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction. Its lead drug candidate is prexigebersen, which is in Phase II clinical trials for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome. It is also developing BP1001-A that is in Phase I clinical trial for the treatment of solid tumors; Liposomal Bcl-2 (BP1002), which is in Phase I clinical trial for the treatment of refractory/relapsed lymphoma and chronic lymphocytic leukemia; and Liposomal STAT3 (BP1003) for treating pancreatic cancer, non-small cell lung cancer, and AML. The company was founded in 2007 and is based in Bellaire, Texas.